Molina Healthcare at UBS Global Healthcare Conference - MOLINA HEALTHCARE INC

Financial Performance:

• 2026 earnings guidance is set at a building block of at least $9.50 per share, derived from a base of $5.25 plus $4.00 in "embedded earnings" and adjusted for headwinds/tailwinds; this excludes potential upside from Medical Loss Ratio (MLR) improvements in the legacy Medicaid business, which currently targets 92.6%.
• Premium revenue is projected to grow from $42 billion to $45 billion in 2026; the company expects to harvest $1.50 per share in G&A efficiencies from this growth alone.
• Legacy Medicaid business operates with an MLR target of 92.6%, with any deviation favorably impacting earnings; the company currently generates roughly 1% to 1.5% net income margins in a depressed environment.
• Embedded earnings of $9 per share are strictly incremental, derived from new discrete business (RFPs, acquisitions), not legacy margin improvement; $4.00 is expected to be realized in 2027.
• The company maintains a strong balance sheet with $600 million in cash at the parent level and a debt-to-cap ratio under 45%.

Guidance and Future Outlook:

• Formal forward guidance will be provided in February; current outlook is characterized as "cautious optimism" for 2027.
• Strategic goal is to achieve target operating margins of 2.5% by the end of the planning period (2028-2029), driven by organic growth and strategic M&A.
• 2027 earnings trajectory is front-end loaded (historically 55-70% of annual earnings occur in H1), though specific seasonal allocation for next year remains TBD.
• Florida Kids contract is expected to move from a 5% pre-tax loss in late 2026 to break-even in 2027, driven primarily by medical cost line improvements (approx. 300 bps pickup needed).
• Long-term membership outlook anticipates a ~6% decline in 2027 due to the Work and Benefits Requirement (OB3) and biannual redeterminations, with further potential attrition in 2028.

Business Segments and Product Lines:

• Medicaid: Core trend stabilizes at 4.5%, with total trend projected at 5.5-6.0% due to acuity mix shifts and underfunding catch-ups (approx. 300 bps gap in current rates). LTSS, behavioral health, and high-cost drugs remain the primary cost drivers.
• Medicare: Strategy is shifting to a strict dual-eligible focus in 2027; the company holds a competitive advantage via "Strong Form" Eligible Affiliated Enrollment (EAE), which favors integrated Medicaid/Medicare MCOs over those relying on CSNP workarounds.
• Marketplace (ACA): Significantly reducing footprint to 7 states (5 with meaningful scale) due to risk pool volatility and regulatory instability; no investment in growth until risk pool stability is achieved.
• Florida CMS Kids: Recently launched in October; expected to incur $1.00 per share loss in Q4 2026 (driven by 99% MLR and one-time startup reserves) before moving to break-even in 2027.
• Acquisition Strategy: Pipeline remains active with a focus on distressed non-profit plans; winning 80% of new procurements and retaining 90% of re-procurements.

Market and Competitive Landscape:

• Rate trends for 2027 are anticipated at 6%, contrasting against 5.5-6.0% medical cost trends; if costs trend toward the lower end, MLR will improve.
• States are increasingly implementing rate cell adjustments to account for acuity shifts; 80% of rate changes effective Jan 1st (representing 55% of revenue) are already known in draft/final form.
• Competitive landscape shows a shift toward referenceability in RFPs, with states verifying performance in other states before awarding contracts.
• Dual-eligible market is growing faster than both Medicare and Medicaid segments, supported by states moving toward "Strong Form" EAE to reduce inefficiencies.
• The election results (Democratic sweeps in Senate, House, and governorships) suggest a "tidal wave" that may facilitate Medicaid relaxation of work requirements and potential bipartisan support on pharmacy transparency and IDR reforms.

Risks and Challenges:

• Regulatory Uncertainty: OB3 implementation involves 6% membership headwinds and uncertainty regarding the pace of disenrollment and frailty definitions, though recent court rulings (Massachusetts vs. Oz) may soften the impact by delaying implementation and extending documentation windows.
• California UIS: Federal regulations requiring undocumented members to revert to fee-for-service will create a $0.20-$0.25 per share headwind in 2027.
• Marketplace Volatility: High sensitivity to rule changes regarding CSRs, subsidies, and enrollment periods makes the segment unviable until stability is demonstrated.
• Acquisition Execution: Delays in contract certifications (e.g., Georgia, Texas) push revenue recognition into 2028, requiring capital readiness to be timed correctly.
• Underfunding: Industry-wide underfunding of Medicaid rates by approximately 300 basis points remains a persistent challenge to margin recovery.

Management Commentary and Tone:

• Tone is confident and forward-looking, describing the 2026 period as a "trough" with clear recovery signals for 2027.
• Management emphasizes disciplined cost management, noting that G&A efficiencies are being harvested despite shrinking legacy books due to significant premium revenue growth.
• Confidence is high in the company's ability to profitably manage new large-scale contracts (e.g., Florida), citing a historical 300 bps outperformance over the market.
• Leadership views the current environment as favorable for M&A, as struggling non-profits are forced to transition, offering acquisition targets at organic growth multiples.

Analyst Questions and Answers:

• Q: What are the specific drivers of the $4 embedded earnings harvest in 2027? A: $1.50 from Florida Kids break-even, $1.00 from exiting the MAPD general issue Medicare business (a $1 loss currently), and $1.50 from G&A leverage on premium revenue growth.
• Q: How will the medical frailty rule change impact disenrollment? A: The struck-down rule and subsequent court rulings provide a "softer landing" with delayed implementation (May 1st deadline) and a six-month documentation window, allowing states more flexibility.
• Q: Are natural growth factors included in the $9.50 build? A: No, the $9.50 is a baseline; natural growth is reflected in the revenue projection ($42B to $45B), and any further margin improvement in legacy Medicaid MLR (below 92.6%) is pure upside.
• Q: How does the company manage readiness costs for delayed state launches? A: Costs are known and built into the financial plan; timing shifts (e.g., Georgia/Texas) do not impact expense recognition but merely delay revenue recognition.
• Q: What is the outlook for Medicare C-SNP workarounds? A: Likely to diminish as states and members prefer the integrated experience of EAE; C-SNPs are viewed as a workaround for non-Medicaid players but fly in the face of integrated care trends.

Other Key Points:

• The company retains 80% of new procurement wins and 90% of re-procurements, indicating strong operational execution despite market protests.
• Capital allocation priority remains: 1) Organic Growth (50% ROE), 2) M&A, 3) Share Repurchases; this hierarchy does not change even during the earnings trough.
• The company is not capital-constrained; the primary bottleneck for growth is the M&A and RFP pipelines, not liquidity.
• Political shifts suggest potential state-level Medicaid expansion discussions, though funding constraints post-OB3 remain a limiting factor for new expansion.